

Do Alcohol-Metabolizing Enzyme Gene Polymorphisms Increase the Risk of Alcoholism and Alcoholic Liver Disease?

Elias Zintzaras,¹ Ioannis Stefanidis,² Mauro Santos,³ and Francesc Vidal⁴

Case-control studies that have investigated the association between alcoholism and alcohol-induced liver damage and the *ADH2*, *ADH3*, *CYP2E1*, and *ALDH2* polymorphisms have reported controversial or inconclusive results. Thus, we conducted a meta-analysis of 50 association studies of the above polymorphisms. We explored potential sources of heterogeneity and bias, performed subgroup analyses by racial background and sex, performed sensitivity analyses for studies not in Hardy-Weinberg equilibrium, and performed a subgroup analysis for cases that met strict criteria for alcoholism. The present meta-analysis underscores significant associations of *ADH2*1*, *ADH3*2*, and *ALDH2*1* alleles and the risk of alcoholism (OR = 1.89 [95% CI 1.56-2.28], 1.32 [95% CI 1.12-1.57], and 4.35 [95% CI 3.04-6.23], respectively). The subsequent subgroup analyses showed association for *ADH2*1* and *ADH3*2* only in East Asians (OR = 2.23 [95% CI 1.81-2.74] and 1.91 [95% CI 1.45-2.53], respectively) and East Asian males (OR = 2.21 [95% CI 1.57-3.10], 1.69 [95% CI 1.10-2.59], respectively). In East Asian males, the OR for *ALDH2*1* was 3.66 (95% CI 1.68-7.96). In Caucasians, sensitivity analysis revealed an association for *ADH2*1* in alcoholism (OR = 1.62 [95% CI 1.22-1.89]). When strict criteria were imposed, the pattern of results remained unaltered. For liver disease, there were no significant associations for *ADH2*1*, *ADH3*2*, or *ALDH2*1* in all subpopulations. The *CYP2E1* polymorphism showed no association whatsoever. There is evidence that alleles are mainly dominant. **In conclusion**, there was heterogeneity between studies in alcoholism for *ADH2*, *ADH3*, and *ALDH2*, and lack of bias in all polymorphisms. The above findings reinforce the need for more rigorous studies, and for regular synthesis of studies' results. *Supplementary material for this article can be found on the HEPATOLOGY website (<http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html>). (HEPATOLOGY 2006;43:352-361.)*

Over the last few years, an increasing number of studies have provided compelling evidence for the involvement of genetically defined predisposing factors in alcoholism and alcohol-induced cirrhosis. The strongest support comes from the fact that not all

subjects with a high daily intake of alcohol develop alcohol-induced liver disease. Mostly metabolized in the liver by the successive action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), the rate of conversion of ingested ethanol to acetaldehyde, and of acetaldehyde to acetate, is influenced by genetic polymorphisms at both loci. *ALDH2* is the most important gene that affects predisposition to alcoholism in Asian populations. Thus, the prevalence in these populations of the inactive ALDH enzymatic form encoded by the *ALDH2*2* allele appears to protect against alcoholism.¹ Furthermore, alcoholics with this inactive allele may be at great risk for advanced alcoholic liver disease.²⁻⁴

Regarding the *ADH* gene cluster, polymorphisms are also detected at the *ADH2* and *ADH3* loci with two alleles (referred to as *1 and *2) each. Alleles *ADH2*2* and *ADH3*1* encode, respectively, for the highly active β_2 and γ_1 allozymes,⁵ and a low prevalence of both alleles has been reported in alcoholic Asians—although some studies did not detect associations between *ADH3* polymor-

Abbreviations: ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; HWE, Hardy-Weinberg equilibrium; FE, fixed effect; RE, random effect.

From the Departments of ¹Biomathematics and ²Internal Medicine, University of Thessaly School of Medicine, Larissa, Greece; ³Department de Genètica i de Microbiologia, Grup de Biologia Evolutiva (GBE), Universitat Autònoma de Barcelona, Barcelona, Spain; and the ⁴Department of Internal Medicine, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain.

Received June 1, 2005; accepted November 15, 2005.

Supported in part by the Red de Centros de Metabolismo y Nutrición C03/08 (F.V.) and Fundación Ramón Areces (M.S.).

Address reprint requests to: Elias Zintzaras, Ph.D., Department of Biomathematics, University of Thessaly School of Medicine, Papakyriazy 22, Larissa 41222, Greece. E-mail: zintza@med.uth.gr; fax: (30) 2410-565270.

Copyright © 2006 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.21023

Potential conflict of interest: Nothing to report.




Fig. 1. *ADH2* polymorphism and the risk of (A) alcoholism and (B) liver disease: contrast of allele *1 against *2. Each study is shown by an OR estimate with the corresponding 95% CI. The horizontal axis is plotted on a log scale. HWE, Hardy-Weinberg equilibrium.

phism and alcoholism in these populations. On the other hand, the results are far less conclusive for Caucasians because here allele *ADH2**2 is found at very low frequency.⁶ In addition, there is evidence that *ADH2**2 and *ADH3**1 alleles are in linkage disequilibrium,^{7,8} which clearly indicates that their contribution to the associated risk of alcoholism is not independent.

The cytochrome *CYP*₄₅₀*2E1* is also involved in alcohol metabolism—though to a lesser extent than *ADH* and *ALDH*—and can be induced in the human liver via chronic alcohol administration.⁹ This gene is also polymorphic, and 2 point mutations in the 5' flanking region (*Pst*-I, *Rsa*-I) that are in close linkage disequilibrium are




Fig. 2. *ADH3* polymorphism and the risk of (A) alcoholism and (B) liver disease: contrasts of allele *2 against *1. Each study is shown by an OR estimate with the corresponding 95% CI. The horizontal axis is plotted on a log scale. HWE, Hardy-Weinberg equilibrium.

known to alter the transcriptional activity of the gene.¹⁰ These point mutations produce the *CYP2E1**1 (*c1*) and *CYP2E1**2 (*c2*) alleles and have been reported to be associated with alcoholic liver disease in Japanese subjects.¹¹ As for the *ADH2* polymorphism, the association is far less clear in Caucasians.

The case–control studies that have investigated the association between alcoholism and alcohol-induced liver damage—as well as the *ADH2*, *ADH3*, *CYP2E1*, and *ADLH2* polymorphisms—provide some controversial or nonconclusive results, partly because each typically involved few cases and few controls and, therefore, there was not enough information to demonstrate association.¹² Furthermore, the interpretation is complicated by the fact that different populations, sampling strategies, genotyp-




Fig. 3. *ALDH2* polymorphism and the risk of (A) alcoholism and (B) liver disease: contrasts of allele *1 against *2. Each study is shown by an OR estimate with the corresponding 95% CI. The horizontal axis is plotted on a log scale. HWE, Hardy-Weinberg equilibrium.

ing procedures, and number of loci included in the analyses have been used.

Meta-analysis is an invaluable means of shedding some light on these contradictory results, as well as to decrease the uncertainty of the effect size of estimated risk.¹³ Two meta-analyses regarding the role of the genetics of alcoholism and alcoholic liver disease have been previously described, but they were restricted to the role of *ADH* and included the relatively scarce information available at the time of the analysis.^{14,15} We report the results of a large meta-analysis of individual patient data regarding *ADH2*, *ADH3*, *ALDH2*, and *CYP2E1* polymorphisms and their associations with alcoholism and alcoholic liver disease.

Materials and Methods

Selection of Studies. All studies published before January 2005 were identified by extended computer-based




Fig. 4. *CYP2E1* polymorphism and the risk of (A) alcoholism and (B) liver disease: contrasts of allele *1 against *2. Each study is shown by an OR estimate with the corresponding 95% CI. The horizontal axis is plotted on a log scale.

searches of the PubMed database. As a search criterion, the following entries were used: *polymorphism*, *ADH2*, *ADH1B*, *ADH3*, *ADH1C*, *CYP4502E1*, *CYP450IE1*, *CYP2E1*, or *ALDH2* and *alcoholism*, *alcohol*, *alcoholic liver disease*, or *liver disease*. The retrieved studies were then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. All references cited in the studies were also reviewed to identify additional published work not indexed by PubMed. Case reports, editorials, and review articles were excluded. The search was restricted to articles written in English.

Case-control studies that determined the distribution of *ADH2*, *ADH3*, *CYP2E1*, *Pst-1/Rsa-1*, and *ALDH2* genotypes in cases with alcoholism, or alcohol-induced liver disease, and in a control group, were eligible for inclusion

Table 1. Random Effect ORs (95% CI) for Various Contrasts and Subpopulations

ADH2 Alcoholism			ADH3 Alcoholism										
1 vs. 2	All	1.89 (1.56, 2.28)	2 vs. 1	All	1.32 (1.12, 1.57)								
	Caucasians	1.29 (0.80, 2.02)		East Asians	1.91 (1.45, 2.53)								
	East Asians	2.23 (1.81, 2.74)		Caucasians	1.03 (0.88, 1.20)								
	All HWE	1.99 (1.68, 2.35)		All HWE	1.40 (1.11, 1.76)								
	East Asians HWE	2.18 (1.76, 2.70)		Caucasians HWE	0.99 (0.79, 1.23)								
	Caucasians HWE	1.52 (1.22, 1.89)*		Males	1.20 (0.68, 2.13)								
	Males	2.15 (1.60, 2.88)		East Asian males	1.69 (1.10, 2.59)*								
	Caucasian males	1.68 (0.80, 3.53)		Strict all	1.36 (1.15, 1.62)								
	East Asian males	2.21 (1.57, 3.10)		Strict Caucasians	1.06 (0.91, 1.24)								
	Caucasian females	1.00 (0.17, 5.78)		Strict East Asians	1.91 (1.45, 2.53)								
	Strict all	1.91 (1.57, 2.34)		Recessive model	All	1.35 (1.07, 1.71)							
	Strict Caucasians	1.26 (0.77, 2.06)		All HWE	1.42 (0.99, 2.02)								
	Strict East Asians	2.02 (1.55, 2.64)		East Asians	2.74 (1.33, 5.65)								
	Recessive model	All		2.62 (1.88, 3.66)	East Asian males	6.99 (0.84, 58.45)*							
East Asians		4.73 (3.14, 7.11)	Strict all	1.39 (1.08, 1.78)									
All HWE		2.74 (2.03, 3.68)	Strict East Asians	3.37 (1.90, 5.99)*									
East Asians HWE		4.33 (2.89, 6.48)	Dominant model	All	1.35 (1.08, 1.67)								
Caucasians HWE		1.55 (1.22, 1.95)	All HWE	1.45 (1.12, 1.86)									
Males		2.98 (1.91, 4.66)	East Asians	1.92 (1.44, 2.55)									
Males East			East Asian males	1.61 (1.01, 2.55)*									
Asians		3.84 (2.08, 7.11)	Strict all	1.40 (1.13, 1.74)									
Strict all		2.70 (1.88, 3.88)	Strict East Asians	1.92 (1.44, 2.55)									
Strict East Asians		5.13 (3.38, 7.80)	Liver disease	1 vs. 2	All	1.04 (0.85, 1.27)*							
Dominant model		All			1.87 (1.54, 2.28)	Caucasians	1.02 (0.83, 1.26)*						
		East Asians			1.95 (1.58, 2.40)	East Asians	1.13 (0.57, 3.00)*						
		All HWE			1.94 (1.63, 2.30)	Males	0.89 (0.56, 1.41)*						
		East Asians HWE			1.93 (1.55, 2.40)	ALDH2 Alcoholism	1 vs. 2	All	4.35 (3.04, 6.23)				
	Caucasians HWE	3.80 (1.10, 13.05)			Males			3.66 (1.68, 7.96)					
	Males	1.84 (1.36, 2.48)			Strict all			5.31 (3.80, 7.43)					
	Males East				Recessive model			All	4.16 (2.94, 5.89)				
	Asians	1.90 (1.34, 2.69)			Males			4.04 (1.74, 9.38)					
	Strict all	1.93 (1.58, 2.35)			Strict all			5.00 (3.63, 6.90)					
	Strict East Asians	2.02 (1.64, 2.49)			Dominant model			All	39.77 (12.97, 122)				
	Liver disease	1 vs. 2			All			0.70 (0.52, 0.94)*	Males	5.75 (1.27, 25.93)			
					Caucasians			0.74 (0.45, 1.19)*	Strict all	13.83 (6.28, 30.46)			
					East Asians			0.68 (0.37, 1.25)	Liver disease	1 vs. 2	All	0.73 (0.35, 1.53)*	
			All HWE	0.70 (0.52, 0.94)*	Males			0.49 (0.19, 1.24)*					
Males			0.66 (0.39, 1.12)*	CYP2E1 Alcoholism	1 vs. 2			All			1.13 (0.76, 1.68)*		
Caucasian males			0.93 (0.43, 2.02)*					Caucasians			1.58 (0.76, 3.28)*		
East Asian males			0.56 (0.26, 1.21)*					East Asians			0.97 (0.58, 1.62)*		
Recessive model			All			0.77 (0.51, 1.17)*	Males	1.19 (0.69, 2.05)*					
Dominant model			All			0.49 (0.29, 0.84)*	Caucasian males	1.81 (0.72, 4.55)*					
CYP2E1 Alcoholism			1 vs. 2			All	0.92 (0.82, 1.04)*	CYP2E1 Liver disease			1 vs. 2	All	1.13 (0.76, 1.68)*
						Caucasians	0.82 (0.62, 1.09)*					Caucasians	1.58 (0.76, 3.28)*
						East Asians	0.91 (0.79, 1.06)*					East Asians	0.97 (0.58, 1.62)*
						Males	0.95 (0.70, 1.29)*					Males	1.19 (0.69, 2.05)*
						Strict all	0.95 (0.84, 1.07)*					Caucasian males	1.81 (0.72, 4.55)*
	Strict Caucasians	0.86 (0.65, 1.14)*				Strict East Asians	0.95 (0.81, 1.10)*						
	Strict East Asians	0.95 (0.81, 1.10)*											

*Lack of heterogeneity ($P > .10$) and FE OR.

in the meta-analysis. Observational studies were excluded. In investigating alcoholism, cases were considered alcoholics, including alcoholics with liver disease, based on valid published criteria (DSM-III-R, DSM-IV,

CAGE, SAPS, Feighner, ICD-10) or validated questionnaires; alcohol consumption >40 g/d for at least 5 years; and reported alcohol abuse or dependence. The control group consisted of nonalcoholic subjects. In addition,

strict criteria for defining alcoholism were imposed: diagnosis of cases using valid published criteria and/or alcohol consumption >80 g/d for at least 10 years. Some individuals not fulfilling these criteria were also included if they unequivocally had any type of alcoholic end-organ damage, such as alcoholic cirrhosis or chronic pancreatitis. In investigating alcohol-induced liver disease, cases were considered alcoholics with cirrhosis due to alcoholism. Cirrhosis was diagnosed by histology or clinical, radiological, and endoscopic findings. Studies with cases positive in hepatitis virus were excluded. The controls were alcoholics free of liver disease. In studies with overlapping cases or controls, the most recent and/or largest study with extractable data was included in the meta-analysis. Only studies that used validated genotyping methods were considered, and the distribution of the genotypes in the control group was tested for Hardy-Weinberg equilibrium (HWE) ($P \geq .05$).¹⁶⁻¹⁸ Finally, studies based on pedigree data were excluded because they investigate linkage and not association.¹⁹

Data Abstraction. From each study, the following information was abstracted: first author, journal, year of publication, racial background of the study population, demographics, matching, validity of the genotyping method, and the number of cases and controls for each *ADH2*, *ADH3*, *CYP2E1*, and *ALDH2* genotypes (Appendices A and B, available at the HEPATOLOGY website [http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html]). The frequencies of the alleles and the genotypic distributions were extracted or calculated for both the cases and the controls. In addition, it was recorded whether the genotyping in each study was blinded to clinical status. When studies investigated more than 1 polymorphism, information on linkage disequilibrium and haplotype estimation was recorded.

Meta-analysis. Prior to the main analysis, the significance of the associations between the two alleles of each genotype—namely, *ADH2**1 versus *ADH2**2, *ADH3**2 versus *ADH3**1, *CYP2E1**1 versus *CYP2E1**2, and *ALDH2**1 versus *ALDH2**2—and risk of alcoholism or risk of developing liver damage were evaluated for each study separately. The main analysis examined the overall association of the allele of interest with the risk of alcoholism, or the risk of developing liver damage, relative to the complementary allele. The dominant and recessive contrasts of the allele of interest were also examined. All associations were indicated as ORs with the corresponding 95% CI. A pooled OR was estimated based on the individual ORs.

The heterogeneity between studies was tested using the *Q*-statistic.²⁰ A *P* value of less than .10 was considered significant. The pooled OR was estimated using fixed effect (FE)

(Mantel-Haenszel) and random effect (RE) (DerSimonian and Laird) models.¹⁷ Random effects modeling assumes a genuine diversity in the results of various studies and incorporates to the calculations a between study variance. Therefore, when there was heterogeneity between studies, the pooled OR was estimated using the RE model. Adjusted estimates of OR were considered whenever possible in a separate analysis. A cumulative meta-analysis and recursive meta-analysis were performed for each polymorphism to evaluate the trend of pooled OR for the allele contrast in time.²¹ A differential magnitude of effect in large versus small studies (or publication bias) for the allele contrast was checked using the Egger regression test for funnel plot asymmetry and the Begg-Mazumdar test, which is based on Kendall's tau.^{12,22,23}

The main (or overall) analysis included all available data. Subgroup analysis for each racial background was also performed. Racial background was categorized into 2 main groups: Caucasian and East Asian.²⁴ However, the consistency of genetic effects across these traditionally defined racial groups does not necessarily mean that race-specific genetic effects are exactly the same.²⁴ In addition, subgroup analyses by male and female cases were performed. A subgroup analysis was applied to those studies that fulfilled strict criteria for alcoholism (>80g/day for at least 10 years). Studies with controls not in HWE were subjected to a sensitivity analysis.^{17,18} In sensitivity analysis, the effect of excluding specific studies was examined. Analyses were performed using Meta-Analyst (Lau, Boston, MA), and CVP90.²⁵

Results

Eligible Studies

The literature review identified 239 titles that met the search criteria. Data from 50 studies that investigated the association between any of the *ADH2*, *ADH3*, *CYP2E1*, and *ALDH2* polymorphisms and alcoholism, and alcohol-induced liver disease, met the inclusion criteria and were included in the meta-analysis. Thirty-three studies dealt with *ADH2*,^{2,3,5-8,26-52} 24 dealt with *ADH3*,^{5-8,26,29-32,37-42,45-47,50-55} 23 dealt with *ALDH2*,^{2-3,6,8,11,26-32,37,39-44,46,47,51,56} and 21 dealt with *CYP2E1*.^{6,11,26,31,32,35,41-43,54,57-67} However, the strict criteria for alcoholism were met by 31 studies in *ADH2*,^{2,3,5-8,26,27,29-37,39-52} 23 studies in *ADH3*,^{5-8,26,29-32,37,39-42,45-47,50-55} 21 studies in *ALDH2*,^{2-3,6,8,11,26-27,29-32,37,39-44,46,47,51} and 20 studies in *CYP2E1*.^{6,11,26,31,32,35,41-43,54,57-65,67} To investigate the association between any of the four loci considered and alcohol-induced liver disease, ten studies dealt with *ADH2*,^{5,6,31-33,35,44,49,50,57} six dealt with *ADH3*,^{5,6,31,32,50,57} three dealt with *ALDH2*,^{32,44,57} and

eight dealt with CYP2E1.^{6,31,32,35,57,58,63,67} The studies were published between 1990 and 2004. A list of all the details abstracted from these studies is provided in Supplementary Appendices A and B.

For the determination of the genetic polymorphisms of *ADH2*, *ADH3*, *CYP4502E1*, *Pst-1/Rsa-1*, and *ALDH2*, validated genotyping methods were used in all studies—namely, polymerase chain reaction and restriction of the polymerase chain reaction product with the enzyme corresponding to each polymorphism. In three studies,^{45,49,50} the genetic polymorphisms of the two alcohol dehydrogenase loci (*ADH2* and *ADH3*) were determined from the enzymatic phenotypes (*i.e.*, by electrophoretic differentiation of the ADH isozymes and by measurements of the ADH enzymatic activity in homogenized liver biopsy specimens).

Eight studies in alcoholism^{28,33,38,39,44,56,65,66} and two studies in liver disease^{33,44} reported that the controls were age- or sex-matched. Studies were conducted in various populations of racial background: 24 involved Caucasians,^{5,6,31,33,35,36,38,45,47-52,54,55,58-65} 21 involved East Asians,^{2,3,7,8,11,26-28,32,39-44,46,53,56,57,66,68} and 5 involved other ethnicities (White and Maori, mixed Brazilians, Mexican Americans, Native Americans, mixed Polynesians).^{26,29,30,34,67} In liver disease studies, 12 involved Caucasians,^{5,6,31,33,35,49,50,58-61,63} five involved East Asians,^{2,4,7,32,57} and one involved another ethnicity (mixed Brazilians).⁶⁷ Fourteen studies involved male cases,^{2,3,6,26,28,30,32,35,39,40,43,44,56,59} and two studies provided data for males and females.^{5,36}

Summary Statistics

The genotype distributions are shown in Appendix B. In studies of alcoholism, the distribution of genotypes in the control group departed from HWE in two studies for *ADH2*,^{41,48} in five studies for *ADH3*,^{5,26,29,31,45} in nine studies for *ALDH2*,^{6,8,26,29-31,47,51,56} and in two studies for *CYP2E1*.^{11,60} Because a lack of HWE indicates possible genotyping errors and/or population stratification, a sensitivity analysis was performed excluding studies not in HWE. Although the majority of studies reviewed in this meta-analysis reported on more than two of the investigated polymorphisms, only four of them provided analyses of haplotypes.^{7,8,37,40} Seven studies^{5-8,31,37,40} investigated the existence of linkage disequilibrium, and six demonstrated linkage disequilibrium between *ADH2* and *ADH3*.^{5,7,8,31,37,40} Because all studies provided unadjusted estimates, adjusted pooled OR were not calculated.

Main Results, Subgroup and Sensitivity Analyses

Figures 1 through 4 and Table 1 show the results for the association between the different polymorphisms and the risk of alcoholism or liver disease.

ADH2. For the *ADH2* polymorphism and its relationship to alcoholism, the allele contrast *1 versus *2 showed heterogeneity among studies ($P < .01$), and the RE-pooled OR was significant (OR = 1.89 [95% CI 1.56, 2.28]). In subgroup analysis, the RE-pooled OR for Caucasians was not significant (OR = 1.29 [95% CI 0.82, 2.02]). However, for those studies involving East Asians, the RE-pooled OR was significant (OR = 2.23 [95% CI 1.81, 2.74]). In sensitivity analysis,^{41,48} the RE-pooled ORs remained significant in both the main analysis and in East Asians. On the other hand, the result in Caucasians changed, producing a significant association (FE OR = 1.52 [95% CI 1.22, 1.89]). The recessive (*1/*1 vs. *1/*2 + *2/*2) and dominant (*1/*2 + *1/*1 vs. *2/*2) models for the effect of allele *1 produced the same overall pattern as the allele contrast (RE OR = 2.62 [95% CI 1.88, 3.66] and 1.87 [95% CI 1.54, 2.28], respectively). However, in Caucasians the association was not significant ($P > .05$), whereas in East Asians the opposite trend was detected for the recessive and dominant models (RE OR = 4.73 [95% CI 3.14, 7.11] and 1.95 [95% CI 1.58, 2.40], respectively). On the other hand, the sensitivity analysis for the recessive and dominant models produced the same pattern of results as the overall allele contrasts, both in East Asians and Caucasians. In the subgroup analysis by sex, males produced a significant association for the allele contrast (RE OR = 2.15 [95% CI 1.60, 2.88]). However, Caucasians showed no association, whereas the East Asians did (RE OR = 2.21 [95% CI 1.57, 3.10]). In East Asians, both recessive and dominant models produced significant association. In Caucasian females, there is no association for the allele contrast. The strict meta-analysis produced results similar to those of the extended one: overall, in Caucasians and in East Asians there is significant association for the allele contrast: RE OR = 1.91 [95% CI 1.57, 2.34], 1.26 [95% CI 0.77, 2.06], and 2.02 [95% CI 1.55, 2.64], respectively. The dominant and recessive models produced significant results overall and for East Asians.

Regarding the relationship between the *ADH2* polymorphisms and liver disease, the heterogeneity between studies was not significant ($P > .10$) and the analysis detected an association for the allele contrast *1 vs. *2 (FE OR = 0.70 [95% CI 0.52, 0.94]). However, the association was not significant in East Asians or Caucasians ($P > .05$). The overall analysis produced significant results because it includes more data than the individual analyses by racial background. On the whole, the recessive model for the effect of allele *1 also produced no significant association; however, the dominant model did (FE OR = 0.49 [95% CI 0.29, 0.84]). In the subgroup analysis for males, overall, in Caucasian males, and in East Asian males there

is no significant association ($P > .05$) for the allele contrast.

ADH3. For the *ADH3* polymorphism and its relationship to alcoholism, the allele contrast *2 versus *1 showed heterogeneity among studies ($P < .01$), and the pooled OR was significant (RE OR = 1.32 [95% CI 1.12, 1.57]). There was, however, a substantial difference between East Asians and Caucasians, because a significant association between allele *2 and the risk of alcoholism was detected for the former (RE OR = 1.91 [95% CI 1.45, 2.53]) but not the latter. In sensitivity analysis,^{5,26,29,31,45} the pattern of results was also similar. In a subgroup analysis for the men^{6,32,39} (no study provided data for women), there was no association. However, the lack of association was due to the Caucasians,⁶ because in East Asians the association is significant (OR = 1.69 [95% CI 1.10, 2.59]).

Overall and for East Asians, the recessive model for allele *ADH3**2 (*2/*2 vs. *1/*2 + *1/*1) (RE OR = 1.35 [95% CI 1.07, 1.71] and 2.74 [95% CI 1.33, 5.65], respectively) and the dominant model (*1/*2 + *2/*2 vs. *1/*1) (RE OR = 1.35 [95% CI 1.08, 1.67]) and 1.92 [95% CI 1.44, 2.55], respectively) produced results similar to those of the allele contrast, and the subsequent sensitivity analysis did not alter the results except for the overall recessive model (RE OR = 1.42 [95% CI 0.99, 2.02]). In a strict meta-analysis, the associations were significant overall and for East Asians (RE OR = 1.36 [95% CI 1.15, 1.62] and 1.91 [95% CI 1.45, 2.53], respectively), whereas for the Caucasians the associations were not significant. Both the recessive and dominant models were significant overall and for East Asians.

Concerning the *ADH3* polymorphisms and liver disease, there was no heterogeneity among all studies ($P > .10$) and the association was nonsignificant overall for Caucasians, East Asians, and men. The dominant and recessive models for the allele *ADH3**2 produced nonsignificant associations ($P > .05$) with no heterogeneity ($P > .10$).

ALDH2. For the *ALDH2* polymorphism, all studied individuals but 1 among Mexican Americans²⁶ in alcoholism and 1 among Caucasians³¹ in alcoholic liver disease, were homozygous for the *1/*1 genotype in Caucasians and Americans; therefore, the analysis was restricted to East Asians.^{2-4,8,11,27,28,32,35,37,39-44,46,56,57} There was heterogeneity among studies ($P < .01$), and the allele contrast was highly significant (RE OR = 4.35 [95% CI 3.04, 6.23]). The recessive and dominant models for the effect of allele *ALDH2**1 showed highly significant associations. The sensitivity analysis^{8,56} did not change the pattern of results. In subgroup analysis for men, the allele contrast and the recessive and dominant models were significant.

The analysis based on the strict criteria for alcoholism produced significant results for the allele contrast (RE OR = 5.31 [95% CI 3.80, 7.43]), the dominant contrast, and the recessive contrast.

Regarding liver disease, the allele contrast showed that there was no heterogeneity among studies ($P > .10$), and the association was not significant overall and in men.

CYP2E1. Finally, in no case (*i.e.*, overall, Caucasians, East Asians, men, or strict criteria) was a statistically significant association found between the *CYP2E1* polymorphism and the risk of developing alcoholism or liver disease for the contrasts under investigation. In addition, there was no significant heterogeneity among studies ($P > .10$).

Potential Bias

None of the studies included in the meta-analysis reported that genotyping was performed blinded to clinical status.

For the *ADH2* polymorphism in alcoholism, the cumulative meta-analysis and recursive meta-analysis for the allelic contrast showed that RE OR fluctuated from 0.58 in 1990 (the first study) to 2.1 in 1996 and then remained fairly constant until 2004 (OR = 1.89). Between-study heterogeneity appeared very early, in 1993. Whereas studies published between 1990 and 1995 showed no association (RE OR = 1.54 [95% CI 0.84, 2.84]), a significant association was reported in studies published between 1996 and 2004 (RE OR = 1.84 [95% CI 1.48, 2.27]). In liver disease, RE OR increased from 0.40 in 1992 (the first study) to 0.68 in 1999, then was relatively stable until 2004 (OR = 1.43).

For the *ADH3* polymorphism in alcoholism, the magnitude of RE OR increased from 1.05 in 1990 to 1.57 in 1996, then exhibited a downward trend until 2004 (OR = 1.32). Heterogeneity appeared in 1996. Whereas studies published between 1990 and 1995 showed no association (RE OR = 1.03 [95% CI 0.77, 1.37]), significant association was seen in studies published between 1996 and 2004 (RE OR = 1.42 [95% CI 1.17, 1.73]). In liver disease, the RE OR increased from 0.80 in 1992 (the first study) to 1.13 in 2002, then declined to 1.04 in 2004.

For the *ALDH2* polymorphism in alcoholism, the RE OR experienced a sharp decline from 1994 (the first study) (OR = 41.93) to 1995 (OR = 6.35) and thereafter exhibited a downward trend until 2003 (OR = 4.35). Heterogeneity appeared in 1995 and remained throughout the entire period. In liver disease, the RE OR was not significant in 1995 (OR = 0.48) and then became significant in 1996 (OR = 0.34); it increased in 2001 (OR = 0.95), but it was not significant.

For the *CYP2E1* polymorphism in alcoholism, the RE OR was nonsignificant in the studied period; however, it exhibited an upward trend between 1995 (the first study) (OR = 0.75) and 1999 (OR = 0.93) and then was stabilized throughout the remaining period (OR = 0.93 in 2004). For liver disease, there was an upward trend from 1995 (OR = 0.49) to 2004 (OR = 0.98), with the association being nonsignificant.

The Egger test and the Begg-Mazumdar test indicated that there is no differential magnitude of effect in large versus small studies (*i.e.*, no publication bias) for each polymorphism investigating alcoholism or liver disease ($P > .05$).

Discussion

Why some individuals become alcohol-dependent is an unresolved question. Why some alcoholic individuals develop cirrhosis, while others do not, is also unknown. Because environmental factors do not fully explain this, researchers have sought the answer at the host genetic background. Most research performed so far deals with those genes that codify for ADH, ALDH, and *CYP2E1*, given their critical role in alcohol and acetaldehyde metabolism and the fact that single-point mutations in each of these genes are known to alter protein activity. To partly cover the main limitation of case-control studies (*i.e.*, the low sample sizes in single studies, because usually thousands of individuals are needed to provide convincing information), a meta-analysis offers a robust tool.

The first meta-analysis¹⁴ focused on the *ADH2* and *ADH3* polymorphisms (8 and 5 studies, respectively) in association with alcoholism and on the *ADH2* polymorphism in liver disease (3 studies). An update review¹⁵ for *ADH2* in alcoholism involved 17 studies. A total of 50 different case-control association studies have been analyzed here for the *ADH2*, *ADH3*, *ALDH2*, and *CYP2E1* polymorphisms. Virtually all of the studies were performed in Caucasians and East Asians. Overall, our results indicate that carriers of the *ADH2*1* and *ADH3*2* less active coding enzymatic alleles, and the highly active *ALDH2*1* coding allele (only in East Asians, and probably according to a dominant model), incur an increased risk of alcoholism. In any case, a subset analysis showed that the role of these allelic variants presents some differences between Caucasians and East Asians, with the strongest effect in the latter. Caucasians lack allele *ALDH2*2* and, hence, the role of ALDH cannot be assessed. To conclude, the meta-analysis and the subsequent subgroup and sensitivity analyses supported an association between the *ADH2* polymorphism and alcoholism (which is stronger in East Asians, and in East Asian men, than in Caucasians), and an association for *ADH3* and *ALDH2* which

is basically due to East Asians. The meta-analysis based on strict criteria for alcoholism, produced the same pattern of results as the extended criteria. In liver disease, there is association with *ALDH2*1* as a protective factor under a dominant model. Neither the *ADH2* polymorphism nor the *ADH3* polymorphism have been implicated in the development of liver disease. Allelic variants of *CYP2E1* do not seem to be involved in alcoholism or in alcoholic liver disease.

The results of the meta-analysis were affected by population origin and/or sensitivity analysis for the *ADH2*, *ADH3*, and *ALDH2* polymorphisms, so any conclusion should be interpreted with caution. Our meta-analysis was based on unadjusted estimates. However, a more precise analysis could be performed if adjusted (by sex, age, age at onset) estimates were provided in all studies. In addition, the results depend on the study design and the inclusion criteria of the cases and the controls in each study. One of the difficulties of the present meta-analysis is the extremely heterogeneous definitions of alcoholic cases; thus, the meta-analysis based on strict criteria for alcoholism may overshadow the possible weaknesses of the extended criteria. However, the controls had a relatively low diversity. The genotyping method was not similar across studies.

In conclusion, although this meta-analysis was based on a large amount of subjects, the investigation of genetic associations should be based on large population studies with similar study designs providing subgroup data (*e.g.*, sex). In addition, other probable genetic risk factors interacting with the above polymorphisms should be investigated. Therefore, this meta-analysis could be a guide for future case-control studies investigating the genetic basis of alcoholism and alcohol-induced liver disease.

Acknowledgment: The authors thank Hédi Erdős, librarian of Collegium Budapest, Institute for Advanced Study, for her invaluable assistance with computer-based literature searches while E.Z., I.S., and M.S. were working together at that institute. The constructive criticisms of two anonymous reviewers are highly appreciated.

References

1. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of *ADH2* and *ALDH2* genotypes in different populations. *Hum Genet* 1992;88:344-346.
2. Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. High incidence of *ADH2*1/ALDH2*1* genes among Japanese alcohol dependents and patients with alcoholic liver disease. *HEPATOLOGY* 1996; 23:234-239.
3. Muramatsu T, Wang ZC, Fang YR, Hu KB, Yan H, Yamada K, et al. Alcohol and aldehyde dehydrogenase genotypes and drinking behavior of Chinese living in Shanghai. *Hum Genet* 1995;96:151-154.
4. Chao YC, Liou SR, Chung YY, Tang HS, Hsu CT, Li TK, et al. Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in Chinese patients. *HEPATOLOGY* 1994;19:360-366.

5. Borràs E, Coutelle C, Rosell A, Fernandez-Muixi F, Broch M, Crosas B, et al. Genetic polymorphism of alcohol dehydrogenase in Europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. *HEPATOLOGY* 2000;31:984-989.
6. Vidal F, Lorenzo A, Auguet T, Olona M, Broch M, Gutierrez C, et al. Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease. *J Hepatol* 2004;41:744-750.
7. Osier M, Pakstis AJ, Kidd JR, Lee JF, Yin SJ, Ko HC, et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. *Am J Hum Genet* 1999;64:1147-1157.
8. Chen CC, Lu RB, Chen YC, Wang MF, Chang YC, Li TK, et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. *Am J Hum Genet* 1999;65:795-807.
9. Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. *HEPATOLOGY* 1993;17:236-245.
10. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. *J Biochem (Tokyo)* 1991;110:559-565.
11. Miyatake R, Suwaki H, Nakamura K, Matsuo Y, Iwahashi K. CYP2E1 genotypes and serum LAP in Japanese alcoholics. *Life Sci* 1995;56:1121-1126.
12. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. *J Hum Genet* 2005;50:267-275.
13. Whitehead A. *Meta-analysis of Controlled Clinical Trials*. Chichester, UK: Wiley, 2002.
14. Whitfield JB. Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease. *Alcohol Alcohol* 1997;32:613-619.
15. Whitfield JB. Alcohol dehydrogenase and alcohol dependence: variation in genotype-associated risk between populations. *Am J Hum Genet* 2002;71:1247-1250.
16. Weir BS. *Genetic Data Analysis II: Methods for Discrete Population Genetic Data*. Sunderland, MA: Sinauer Associates, 1996.
17. Zintzaras E, Hadjigeorgiou GM. The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: a meta-analysis. *J Hum Genet* 2005;50:560-566.
18. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. *J Hum Genet* 2004;49:474-481.
19. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. *Genet Epidemiol* 2005;28:123-137.
20. Cochran WG. The combination of estimates from different experiments. *Biometrics* 1954;10:101-129.
21. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. *N Engl J Med* 1992;327:248-254.
22. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-634.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088-1101.
24. Ioannidis JP, Ntzani EE, Trikalinos TA. "Racial" differences in genetic effects for complex diseases. *Nat Genet* 2004;36:1312-1318.
25. Zintzaras E, Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. *J Hum Genet* 2005;50:84-91.
26. Konishi T, Luo HR, Calvillo M, Mayo MS, Lin KM, Wan YJ. ADH1B*1, ADH1C*2, DRD2 (-141C Ins), and 5-HTTLPR are associated with alcoholism in Mexican American men living in Los Angeles. *Alcohol Clin Exp Res* 2004;28:1145-1152.
27. Chao YC, Wang SJ, Chu HC, Chang WK, Hsieh TY. Investigation of alcohol metabolizing enzyme genes in Chinese alcoholics with avascular necrosis of hip joint, pancreatitis and cirrhosis of the liver. *Alcohol Alcohol* 2003;38:431-436.
28. Osaka R, Nanakorn S, Sakata R, Nishiyori A, Shibata A, Nakamura J, et al. Alcohol dehydrogenase-2 and aldehyde dehydrogenase-2 genotypes and male alcohol use disorders in Khon Kaen, north-east Thailand. *Psychiatry Clin Neurosci* 2003;57:37-45.
29. Wall TL, Carr LG, Ehlers CL. Protective association of genetic variation in alcohol dehydrogenase with alcohol dependence in Native American Mission Indians. *Am J Psychiatry* 2003;160:41-46.
30. Chambers GK, Marshall SJ, Robinson GM, Maguire S, Newton-Howes J, Chong NL. The genetics of alcoholism in Polynesians: alcohol and aldehyde dehydrogenase genotypes in young men. *Alcohol Clin Exp Res* 2002;26:949-955.
31. Frenzer A, Butler WJ, Norton ID, Wilson JS, Apte MV, Pirola RC, et al. Polymorphism in alcohol-metabolizing enzymes, glutathione S-transferases and apolipoprotein E and susceptibility to alcohol-induced cirrhosis and chronic pancreatitis. *J Gastroenterol Hepatol* 2002;17:177-182.
32. Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH, et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. *J Korean Med Sci* 2001;16:745-750.
33. Ogurtsov PP, Garmash IV, Miandina GI, Guschin AE, Itkes AV, Moiseev VS. Alcohol dehydrogenase ADH2-1 and ADH2-2 allelic isoforms in the Russian population correlate with type of alcoholic disease. *Addict Biol* 2001;6:377-383.
34. Amadéo S, Noble EP, Fourcade-Amadeo ML, Tetaria C, Brugiroux MF, Nicolas L, et al. Association of D2 dopamine receptor and alcohol dehydrogenase 2 genes with Polynesian alcoholics. *Eur Psychiatry* 2000;15:97-102.
35. Rodrigo L, Alvarez V, Rodriguez M, Perez R, Alvarez R, Coto E. N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study. *Scand J Gastroenterol* 1999;34:303-307.
36. Whitfield JB, Nightingale BN, Bucholz KK, Madden PA, Heath AC, Martin NG. ADH genotypes and alcohol use and dependence in Europeans. *Alcohol Clin Exp Res* 1998;22:1463-1469.
37. Chen WJ, Loh EW, Hsu YP, Cheng AT. Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. *Biol Psychiatry* 1997;41:703-709.
38. Espinós C, Sanchez F, Ramirez C, Juan F, Najera C. Polymorphism of alcohol dehydrogenase genes in alcoholic and nonalcoholic individuals from Valencia (Spain). *Hereditas* 1997;126:247-253.
39. Shen YC, Fan JH, Edenberg HJ, Li TK, Cui YH, Wang YF, et al. Polymorphism of ADH and ALDH genes among four ethnic groups in China and effects upon the risk for alcoholism. *Alcohol Clin Exp Res* 1997;21:1272-1277.
40. Chen WJ, Loh EW, Hsu YP, Chen CC, Yu JM, Cheng AT. Alcohol-metabolizing genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. *Br J Psychiatry* 1996;168:762-767.
41. Nakamura K, Iwahashi K, Matsuo Y, Miyatake R, Ichikawa Y, Suwaki H. Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. *Alcohol Clin Exp Res* 1996;20:52-55.
42. Higuchi S, Matsushita S, Murayama M, Takagi S, Hayashida M. Polymorphisms of ethanol-oxidizing enzymes in alcoholics with inactive ALDH2. *Hum Genet* 1996;97:431-434.
43. Maezawa Y, Yamauchi M, Toda G, Suzuki H, Sakurai S. Alcohol-metabolizing enzyme polymorphisms and alcoholism in Japan. *Alcohol Clin Exp Res* 1995;19:951-954.
44. Yamauchi M, Maezawa Y, Toda G, Suzuki H, Sakurai S. Association of a restriction fragment length polymorphism in the alcohol dehydrogenase 2 gene with Japanese alcoholic liver cirrhosis. *J Hepatol* 1995;23:519-523.
45. Pares X, Farres J, Pares A, Soler X, Panes J, Ferre JL, et al. Genetic polymorphism of liver alcohol dehydrogenase in Spanish subjects: significance

- of alcohol consumption and liver disease. *Alcohol* 1994;29:701-705.
46. Thomasson HR, Crabb DW, Edenberg HJ, Li TK, Hwu HG, Chen CC, et al. Low frequency of the ADH2*2 allele among Atayal natives of Taiwan with alcohol use disorders. *Alcohol Clin Exp Res* 1994;18:640-643.
 47. Gilder FJ, Hodgkinson S, Murray RM. ADH and ALDH genotype profiles in Caucasians with alcohol-related problems and controls. *Addiction* 1993;88:383-388.
 48. Sherman DI, Ward RJ, Warren-Perry M, Williams R, Peters TJ. Association of restriction fragment length polymorphism in alcohol dehydrogenase 2 gene with alcohol induced liver damage. *BMJ* 1993;307:1388-1390.
 49. Vidal F, Perez J, Panisello J, Toda R, Gutierrez C, Richart C. Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease. *Alcohol Clin Exp Res* 1993;17:782-785.
 50. Poupon RE, Nalpas B, Coutelle C, Fleury B, Couzigou P, Higuieret D. Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: implication in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol and Liver. *HEPATOLOGY* 1992;15:1017-1022.
 51. Day CP, Bashir R, James OF, Bassendine MF, Crabb DW, Thomasson HR, et al. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. *HEPATOLOGY* 1991;14:798-801.
 52. Couzigou P, Fleury B, Groppi A, Cassaigne A, Begueret J, Iron A. Genotyping study of alcohol dehydrogenase class I polymorphism in French patients with alcoholic cirrhosis. The French Group for Research on Alcohol and Liver. *Alcohol* 1990;25:623-626.
 53. Chao YC, Wang LS, Hsieh TY, Chu CW, Chang FY, Chu HC. Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis. *Am J Gastroenterol* 2000;95:2958-2964.
 54. Grove J, Brown AS, Daly AK, Bassendine MF, James OF, Day CP. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. *Pharmacogenetics* 1998;8:335-342.
 55. Sherman DI, Ward RJ, Yoshida A, Peters TJ. Alcohol and acetaldehyde dehydrogenase gene polymorphism and alcoholism. *EXS* 1994;71:291-300.
 56. Nanakorn S, Fukuda K, Nishiyori A, Shibata A, Nakamura J. Aldehyde dehydrogenase genotypes and male alcohol use disorders: a case-control study in Khon Kaen, north-east Thailand. *Psychiatry Clin Neurosci* 1999;53:397-405.
 57. Chao YC, Young TH, Tang HS, Hsu CT. Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. *HEPATOLOGY* 1997;25:112-117.
 58. Ball DM, Sherman D, Gibb R, Powell JF, Hillman A, Peters T, et al. No association between the c2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. *Drug Alcohol Depend* 1995;39:181-184.
 59. Carr LG, Hartleroad JY, Liang Y, Mendenhall C, Moritz T, Thomasson H. Polymorphism at the P450IIE1 locus is not associated with alcoholic liver disease in Caucasian men. *Alcohol Clin Exp Res* 1995;19:182-184.
 60. Lucas D, Menez C, Floch F, Gourlaouen Y, Sparfel O, Joannet I, et al. Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic caucasians. *Alcohol Clin Exp Res* 1996;20:1033-1037.
 61. Pirmohamed M, Kitteringham NR, Quest LJ, Allott RL, Green VJ, Gilmore IT, et al. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. *Pharmacogenetics* 1995;5:351-357.
 62. Agundez J, Ladero J, Diaz-Rubio M, Benitez J. Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol-related severe liver disease. *Liver* 1996;16:380-383.
 63. Parsian A, Cloninger CR, Zhang ZH. Association studies of polymorphisms of CYP2E1 gene in alcoholics with cirrhosis, antisocial personality, and normal controls. *Alcohol Clin Exp Res* 1998;22:888-891.
 64. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. *Mol Pathol* 2000;53:88-93.
 65. Pastorelli R, Bardazzi G, Saieva C, Cerri A, Gestri D, Allamani A, et al. Genetic determinants of alcohol addiction and metabolism: a survey in Italy. *Alcohol Clin Exp Res* 2001;25:221-227.
 66. Piao YF, Li JT, Shi Y. Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. *World J Gastroenterol* 2003;9:2612-2615.
 67. Burim RV, Canalle R, Martinelli AL, Takahashi CS. Polymorphisms in glutathione S-transferases GSTM1, GSTT1 and GSTP1 and cytochromes P450 CYP2E1 and CYP1A1 and susceptibility to cirrhosis or pancreatitis in alcoholics. *Mutagenesis* 2004;19:291-298.
 68. Chao YC, Young TH, Chang WK, Tang HS, Hsu CT. An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a Chinese population. *HEPATOLOGY* 1995;22:1409-1414.